Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Drug Administration Schedule
Humans
Male
Middle Aged
Neoplasm Metastasis
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Tissue Extracts
/ administration & dosage
prostatic neoplasms
translational medical research
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
11
07
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
6
1
2022
Statut:
ppublish
Résumé
Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metastatic castration resistant prostate cancer (mCRPC). Subjects with asymptomatic or minimally symptomatic mCRPC were randomly assigned in a 1:1 ratio to receive either atezolizumab followed by sipuleucel-T (Arm 1) or sipuleucel-T followed by atezolizumab (Arm 2). The primary endpoint was safety, while secondary endpoints included preliminary clinical activity such as objective tumor response and systemic immune responses that could identify key molecular and immunological changes associated with sequential administration of atezolizumab and sipuleucel-T. A total of 37 subjects were enrolled. The median age was 75.0 years, median prostate specific antigen (PSA) was 21.9 ng/mL, and subjects had a median number of three prior treatments. Most subjects (83.8%) had at least one treatment-related adverse event. There were no grade 4 or 5 toxicities attributed to either study drug. Immune-related adverse events and infusion reactions occurred in 13.5% of subjects, and all of which were grade 1 or 2. Of 23 subjects with Response Evaluation Criteria in Solid Tumors measurable disease, only one subject in Arm 2 had a partial response (PR) and four subjects overall had stable disease (SD) at 6 months reflecting an objective response rate of 4.3% and a disease control rate of 21.7%. T-cell receptor diversity was higher in subjects with a response, including SD. Immune response to three novel putative antigens (SIK3, KDM1A/LSD1, and PIK3R6) appeared to increase with treatment. Overall, regardless of the order in which they were administered, the combination of atezolizumab with sipuleucel-T appears to be safe and well tolerated with a comparable safety profile to each agent administered as monotherapy. Correlative immune studies may suggest the combination to be beneficial; however, further studies are needed. NCT03024216.
Sections du résumé
BACKGROUND
Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metastatic castration resistant prostate cancer (mCRPC).
METHODS
Subjects with asymptomatic or minimally symptomatic mCRPC were randomly assigned in a 1:1 ratio to receive either atezolizumab followed by sipuleucel-T (Arm 1) or sipuleucel-T followed by atezolizumab (Arm 2). The primary endpoint was safety, while secondary endpoints included preliminary clinical activity such as objective tumor response and systemic immune responses that could identify key molecular and immunological changes associated with sequential administration of atezolizumab and sipuleucel-T.
RESULTS
A total of 37 subjects were enrolled. The median age was 75.0 years, median prostate specific antigen (PSA) was 21.9 ng/mL, and subjects had a median number of three prior treatments. Most subjects (83.8%) had at least one treatment-related adverse event. There were no grade 4 or 5 toxicities attributed to either study drug. Immune-related adverse events and infusion reactions occurred in 13.5% of subjects, and all of which were grade 1 or 2. Of 23 subjects with Response Evaluation Criteria in Solid Tumors measurable disease, only one subject in Arm 2 had a partial response (PR) and four subjects overall had stable disease (SD) at 6 months reflecting an objective response rate of 4.3% and a disease control rate of 21.7%. T-cell receptor diversity was higher in subjects with a response, including SD. Immune response to three novel putative antigens (SIK3, KDM1A/LSD1, and PIK3R6) appeared to increase with treatment.
CONCLUSIONS
Overall, regardless of the order in which they were administered, the combination of atezolizumab with sipuleucel-T appears to be safe and well tolerated with a comparable safety profile to each agent administered as monotherapy. Correlative immune studies may suggest the combination to be beneficial; however, further studies are needed.
TRIAL REGISTRATION NUMBER
NCT03024216.
Identifiants
pubmed: 34376554
pii: jitc-2021-002931
doi: 10.1136/jitc-2021-002931
pmc: PMC8356194
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Tissue Extracts
0
atezolizumab
52CMI0WC3Y
sipuleucel-T
8Q622VDR18
Banques de données
ClinicalTrials.gov
['NCT03024216']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MZ, RW, AD, WH and JS are employees of Serimmune. CR received funding from Dendreon for the conduct of this study.
Références
Clin Cancer Res. 2009 May 15;15(10):3251-5
pubmed: 19447877
J Immunother Cancer. 2015 Jun 16;3:23
pubmed: 26085931
Cancer. 2019 Dec 1;125(23):4172-4180
pubmed: 31483485
Hum Genet. 2020 Jun;139(6-7):783-794
pubmed: 32419033
Sci Transl Med. 2014 May 28;6(238):238ra70
pubmed: 24871131
Cancer Immunol Immunother. 2013 Jan;62(1):137-47
pubmed: 22865266
Sci Rep. 2017 Sep 21;7(1):12078
pubmed: 28935958
Clin Cancer Res. 2019 Jun 1;25(11):3220-3228
pubmed: 30770348
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Front Immunol. 2021 Apr 27;12:625311
pubmed: 33986742
N Engl J Med. 2018 Apr 12;378(15):1408-1418
pubmed: 29420164
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Prostate. 2019 Jun;79(9):969-979
pubmed: 30999388
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Clin Cancer Res. 2015 Aug 15;21(16):3619-30
pubmed: 25649018
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Asian J Androl. 2014 May-Jun;16(3):378-86
pubmed: 24759575
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Eur Urol. 2020 Dec;78(6):822-830
pubmed: 32811715
J Clin Oncol. 2006 Jul 1;24(19):3089-94
pubmed: 16809734
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10988-E10997
pubmed: 30373828
J Allergy Clin Immunol. 2014 Apr;133(4):1109-15
pubmed: 24406074
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Signal Transduct Target Ther. 2020 Aug 12;5(1):150
pubmed: 32788639
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Eur Urol. 2015 Aug;68(2):325-34
pubmed: 25108577
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100
pubmed: 29346180
Sci Rep. 2020 Mar 24;10(1):5294
pubmed: 32210339
Nucleic Acids Res. 2009 Jan;37(Database issue):D816-9
pubmed: 18838390
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
J Clin Invest. 2010 Aug;120(8):2715-30
pubmed: 20644256
Hum Pathol. 2019 May;87:95-102
pubmed: 30851334
Adv Ther. 2020 Dec;37(12):4910-4929
pubmed: 33029725
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65
pubmed: 20823238
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
J Natl Cancer Inst. 2014 Sep 24;106(11):
pubmed: 25255802
Cancer Res. 2010 Nov 1;70(21):8388-97
pubmed: 20959478
Front Oncol. 2019 Aug 02;9:721
pubmed: 31428587